Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1425205 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $4.70Day −4.08%Mkt cap $2.1B1Y +59.3%Off 52W high −16.7%Vol (1Y) 94.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,960 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest22.4% of sh out |
| Days to cover5.9d |
| 13F net flow (QoQ)+0.18% |
| Top-10 13F concentration57.5% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$285.6M |
| Earnings (TTM)-$353.9M |
| ROE−55.5% |
| Net margin−148.4% |
| ROIC−80.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+72.2% |
| 1Y+59.3% |
| 3Y−34.7% |
| 5Y−79.5% |
| 10Y−45.5% |
| Since incept. (ann.)−18.1% |
Total return through 2026-07-28 · series begins 2010-10-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)94.8% |
| Ann. volatility (3Y)95.9% |
| Sharpe (1Y)0.96 |
| Sharpe (3Y)0.34 |
| Max drawdown (1Y)−39.0% |
| Max drawdown (3Y)−90.5% |
| Beta (3Y vs SPY)2.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 31.1M | $109M | 6.96% | +5.3% |
| MHR FUND MANAGEMENT LLC | 29.0M | $102M | 6.49% | +0.0% |
| STATE STREET CORP | 17.4M | $61M | 3.91% | −13.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.6M | $58M | 3.72% | new |
| TWO SIGMA INVESTMENTS, LP | 13.7M | $48M | 3.07% | +211.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11.7M | $41M | 2.62% | new |
| MILLENNIUM MANAGEMENT LLC | 9.4M | $33M | 2.11% | +43.0% |
| GOLDMAN SACHS GROUP INC | 8.8M | $31M | 1.96% | +1.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.19 | — | $71.4M | +44.8% |
| 2025-12-31 | 2026-02-24 | — | — | $86.8M | +17.7% |
| 2025-09-30 | 2025-11-06 | — | — | $67.5M | +15.2% |
| 2025-06-30 | 2025-08-07 | −$0.33 | — | $60.0M | +92.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
